NATALIZUMAB IN MULTIPLE SCLEROSIS – A REVIEW OF DIFFERENT DOSING REGIMENS, SIDE EFFECTS, COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES WITH ADDITIONAL ATTENTION TO USE IN PREGNANCY AND THE PEDIATRIC POPULATION
Authors:
- Zuzanna LechowskaZLZuzanna Lechowska
- Gabriela PiotrowskaGPGabriela Piotrowska
- Agnieszka Anna GaczołAGAgnieszka Anna Gaczoł
- Wiktoria KrólWKWiktoria Król
- Konrad KulkaKKKonrad Kulka
- Dominika JurczakDJDominika Jurczak
- Julia Koronczok-MatusiakJKJulia Koronczok-Matusiak
- Zuzanna KafaraZKZuzanna Kafara
- Donata KowalczykDKDonata Kowalczyk
- Agnieszka KafaraAKAgnieszka Kafara
- Rafał SzarekRSRafał Szarek
- Katarzyna MichtaKMKatarzyna Michta
Open Access
- 25 August 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Abstract
Objective: The aim of this review was to evaluate the clinical efficacy, optimization of dosing regimens, safety profile, and socioeconomic aspects of natalizumab (NTZ) use in the treatment of multiple sclerosis (MS), with a additional focus on pregnant and pediatric populations. Methodology: A systematic review of the PubMed database was conducted, identifying 220 records. Thirty-two publications meeting the criteria regarding the mechanism of action, efficacy, adverse event profile, and comparison with other disease-modifying therapies (DMTs) were included in the final analysis. Results: The analysis demonstrated that the extended interval dosing (EID, every 6 weeks) regimen maintains clinical and radiological efficacy comparable to the standard interval dosing (SID, every 4 weeks), while significantly reducing the risk of progressive multifocal leukoencephalopathy (PML) by 88–94%. It was recognized that natalizumab is safer than other DMTs, such as ocrelizumab, without compromising efficacy. In the pediatric population, NTZ showed the highest efficacy in reducing relapse rates compared to fingolimod and injectable therapies. In pregnant women, continuing treatment until the 34th week prevents postpartum rebound relapses and improves EDSS scores, showing no teratogenic effects. Economically, the subcutaneous form of NTZ and the use of EID generate significant direct and societal cost savings. Conclusions: Natalizumab remains a highly effective and cost-efficient therapeutic option for the treatment of relapsing-remitting MS. Personalization of treatment through the EID regimen and the subcutaneous formulation allows for an improved safety profile and patient quality of life, while simultaneously reducing the systemic burden on healthcare.Keywords
This publication has 32 references indexed in Scilit:
- Maternal and neonatal outcomes following natalizumab use during pregnancy in women with multiple sclerosis: A multicenter observational studyJournal of Clinical Neuroscience, 2026
- A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND studyMultiple Sclerosis and Related Disorders, 2026
- Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR)Journal of Neurology, 2025
- Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumabJournal of the Neurological Sciences, 2025
- Profiling the Cerebrospinal Fluid Proteome in Progressive Multiple Sclerosis: Treatment Effects and Associations with IgM Oligoclonal BandsJournal of Neuroimmune Pharmacology, 2025
- Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing–Remitting Multiple SclerosisPharmacoEconomics, 2025
- Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximabMultiple Sclerosis and Related Disorders, 2025
- A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosisAnnals of Clinical and Translational Neurology, 2024
- Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?Neurotherapeutics, 2019
- Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitorBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2009